Studies by Hancock and colleagues have shown that the L-type calcium channel blocker fendiline specifically elicits cytotoxicity in K-Ras mutant cancer cells by interfering with K-Ras localization at the membrane [37,38,39]. Here, KRAS is linked to cancer.